title: Anaemia, diabetes and chronic kidney disease: where are we now?
abstract: Anaemia is a common finding in people with diabetes and chronic kidney disease and failure of the kidney to produce erythro-poietin in response to a falling haemoglobin concentration is a key component, correlating with the degree of albuminuria, renal dysfunction and iron deficiency. Anaemia in diabetes is associated with a number of adverse outcomes, including increased risk of all cause and cardiovascular mortality. Whether or not anaemia is a marker or mediator of adverse outcome still remains to be completely resolved. Treatment of anaemia in diabetes has quality of life benefits and reduces transfusion requirements. Correction of anaemia to normal haemoglobin concentrations is associated with significant adverse cardiovascular outcomes and is not recommended, escalating doses of erythropoiesis-stimulating agents should be avoided. The treatment of anaemia in people with diabetes and chronic kidney disease should begin with optimisation of iron stores. An aspirational haemoglobin concentration range of 10-12 g/dl with anaemia management, balances proven benefits of anaemia treatment with potential cardiovascular risk.
authors.affiliation: Kent and Canterbury Hospital, Canterbury, Kent, UK. paul.stevens@ekht.nhs.uk
authors.forename: P E
authors.initials: PE
authors.lastname: Stevens
mesh_terms: D000740:Anemia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D048909:Diabetes Complications / Q000188:drug therapy*; D003928:Diabetic Nephropathies / Q000150:complications* / Q000188:drug therapy; D004921:Erythropoietin / Q000172:deficiency / Q000627:therapeutic use*; D006397:Hematinics / Q000627:therapeutic use; D006801:Humans; D007501:Iron / Q000627:therapeutic use*; D000090463:Iron Deficiencies; D051436:Renal Insufficiency, Chronic / Q000150:complications* / Q000188:drug therapy
chemical_list: D006397:Hematinics; D004921:Erythropoietin; D007501:Iron